

Special Issue

Gynecological Diseases in Cellular and Molecular Perspectives

Message from the Guest Editors

Gynaecological diseases are a heterogeneous group of conditions of the female reproductive tract, including malignancies, benign tumors, endometriosis, polycystic ovarian syndrome, menstrual disorders, and others. It should be highlighted that they are not only the leading cause of women's mortality worldwide but also lead to significant deterioration in quality of life. Despite the development of new tools in the diagnosis and treatment of gynaecological diseases, the prognosis for patients remains poor, especially in ovarian cancer. In both early diagnosis and the treatment of gynaecological pathologies, it is necessary to investigate the molecular background to deepen the current knowledge and understanding of cellular interactions, including immune checkpoints (PD-1/PD-L1, TIGIT/CD155/DNAM-1, TIM-3/Gal-9 pathways etc.). Molecular profiling, including genomic profiling, microsatellite instability status, tumor mutational burden, immune/molecular biomarkers, and microRNAs, is also predominant for clinical management.

Guest Editors

Prof. Dr. Iwona Wertel

Independent Laboratory of Cancer Diagnostics and Immunology, I Chair and Department of Oncological Gynaecology and Gynaecology, Medical University in Lublin, Chodźki 1, 20-093 Lublin, Poland

Dr. Anna Pawłowska-Łachut

Independent Laboratory of Cancer Diagnostics and Immunology, Medical University of Lublin, Chodźki 1, 20-093 Lublin, Poland

Deadline for manuscript submissions

30 September 2026



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



mdpi.com/si/217757

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).